Literature DB >> 28258194

Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagasic Patients.

Jose Mateus1,2, Elena Pérez-Antón3, Paola Lasso1,2, Adriana Egui3, Nubia Roa4, Bartolomé Carrilero5, John M González6, M Carmen Thomas3, Concepción J Puerta2, Manuel C López7, Adriana Cuéllar8.   

Abstract

Chagas disease is a chronic infection caused by Trypanosoma cruzi, an intracellular protozoan parasite. Chronic chagasic patients (CCPs) have dysfunctional CD8+ T cells that are characterized by impaired cytokine production, high coexpression of inhibitory receptors, and advanced cellular differentiation. Most patients diagnosed in the chronic phase of Chagas disease already exhibit heart involvement, and there is no vaccination that protects against the disease. Antiparasitic treatment is controversial as to its indication for this stage of the disease. There is a lack of biological markers to evaluate the effectiveness of antiparasitic treatment, and little is known about the effect of the treatment on CD8+ T cells. Thus, the aim of the current study was to analyze the early effects of antiparasitic treatment on CD8+ T cells from CCPs with asymptomatic clinical forms of disease. To evaluate the CD8+ T cell subsets, expression of inhibitory receptors, and functionality of T cells in CCPs, PBMCs were isolated. The results showed that treatment of CCPs with the asymptomatic form of the disease induces an increase in the frequency of CD8+ central memory T cells and terminal effector T cells, a decrease in the coexpression of inhibitory receptors, an improved Ag-specific CD8+ T cell response exhibited by the individual production of IFN-γ or IL-2, and a multifunctional CD8+ T cell profile of up to four functions (IFN-γ+IL-2+Perforin+Granzyme B+). These findings suggest that, in CCPs, antiparasitic treatment improved the quality of Ag-specific CD8+ T cell responses associated with a decrease in inhibitory receptor coexpression, which could serve as biomarkers for monitoring the effectiveness of antiparasitic treatment.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28258194     DOI: 10.4049/jimmunol.1602095

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Understanding CD8+ T Cell Immunity to Trypanosoma cruzi and How to Improve It.

Authors:  Eva V Acosta Rodríguez; Cintia L Araujo Furlan; Facundo Fiocca Vernengo; Carolina L Montes; Adriana Gruppi
Journal:  Trends Parasitol       Date:  2019-10-10

2.  A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.

Authors:  Ana Fernández-Villegas; Elena Pérez-Antón; Inmaculada Gómez; Adriana Egui; M Carmen Thomas; Bartolomé Carrilero; Ángel Del Pozo; Maialen Ceballos; Eduardo Andrés-León; Miguel Ángel López-Ruz; Eusebio Gainza; Enrique Oquiñena; Manuel Segovia; Manuel Carlos López
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.

Authors:  María Gabriela Álvarez; Juan Carlos Ramírez; Graciela Bertocchi; Marisa Fernández; Yolanda Hernández; Bruno Lococo; Constanza Lopez-Albizu; Alejandro Schijman; Carolina Cura; Marcelo Abril; Susana Laucella; Rick L Tarleton; María Ailen Natale; Melisa Castro Eiro; Sergio Sosa-Estani; Rodolfo Viotti
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 4.  Chronic Chagas Disease-the Potential Role of Reinfections in Cardiomyopathy Pathogenesis.

Authors:  Christian Olivo Freites; Hendrik Sy; Amal Gharamti; Nelson I Agudelo Higuita; Carlos Franco-Paredes; José Antonio Suárez; Andrés F Henao-Martínez
Journal:  Curr Heart Fail Rep       Date:  2022-08-11

5.  Role of the PD-1/PD-L1 Pathway in Experimental Trypanosoma cruzi Infection and Potential Therapeutic Options.

Authors:  Yanina Arana; Rosa Isela Gálvez; Thomas Jacobs
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 6.  Pathology and Pathogenesis of Chagas Heart Disease.

Authors:  Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

Review 7.  The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease.

Authors:  Gonzalo R Acevedo; Magalí C Girard; Karina A Gómez
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

8.  Phenotypic and Functional Profiles of Antigen-Specific CD4+ and CD8+ T Cells Associated With Infection Control in Patients With Cutaneous Leishmaniasis.

Authors:  Adriana Egui; Darién Ledesma; Elena Pérez-Antón; Andrés Montoya; Inmaculada Gómez; Sara María Robledo; Juan José Infante; Ivan Darío Vélez; Manuel C López; M Carmen Thomas
Journal:  Front Cell Infect Microbiol       Date:  2018-11-19       Impact factor: 5.293

9.  Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.

Authors:  Elena Pérez-Antón; Adriana Egui; M Carmen Thomas; Concepción J Puerta; John Mario González; Adriana Cuéllar; Manuel Segovia; Manuel Carlos López
Journal:  PLoS Negl Trop Dis       Date:  2018-05-11

10.  Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes.

Authors:  María C Albareda; María A Natale; Ana M De Rissio; Marisa Fernandez; Alicia Serjan; María G Alvarez; Gretchen Cooley; Huifeng Shen; Rodolfo Viotti; Jacqueline Bua; Melisa D Castro Eiro; Myriam Nuñez; Laura E Fichera; Bruno Lococo; Karenina Scollo; Rick L Tarleton; Susana A Laucella
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.